

From the INTERNATIONAL BUREAU

PCT**NOTIFICATION CONCERNING
TRANSMITTAL OF COPY OF INTERNATIONAL
APPLICATION AS PUBLISHED OR REPUBLISHED**

To:

SIEGEL, Susan, Alpert
Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, OR 97204
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year)

06 January 2005 (06.01.2005)

Applicant's or agent's file reference

4239-68223

IMPORTANT NOTICE

International application No.

PCT/US2004/010588

International filing date (day/month/year)

05 April 2004 (05.04.2004)

Priority date (day/month/year)

08 April 2003 (08.04.2003)

Applicant

THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY,
DEPARTMENT OF HEALTH AND HUMAN SERVICES et al

The International Bureau transmits herewith the following documents:



copy of the international application as published by the International Bureau on under
No. WO



copy of international application as republished by the International Bureau on 06 January 2005 (06.01.2005) under
No. WO 2004/092213

For an explanation as to the reason for this republication of the international application, reference is made to INID codes (15), (48)
or (88) (as the case may be) on the front page of the attached document.

BEST AVAILABLE COPY

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Athina Nickitas-Etienne

Facsimile No.+41 22 740 14 35

Facsimile No.+41 22 338 89 95

PATENT COOPERATION TREATY

WO 2004/092213
PCT/US2004/010588From the INTERNATIONAL BUREAU *NIH/SAS/UMS***PCT**NOTIFICATION CONCERNING
TRANSMITTAL OF COPY OF INTERNATIONAL
APPLICATION AS PUBLISHED OR REPUBLISHED

To:

SIEGEL, Susan, Alpert
Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, OR 97204
ETATS-UNIS D'AMERIQUEDate of mailing (day/month/year)
28 October 2004 (28.10.2004)Applicant's or agent's file reference
4239-68223

IMPORTANT NOTICE

International application No.
PCT/US2004/010588International filing date (day/month/year)
05 April 2004 (05.04.2004)Priority date (day/month/year)
08 April 2003 (08.04.2003)

Applicant

THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY,
DEPARTMENT OF HEALTH AND HUMAN SERVICES et al

The International Bureau transmits herewith the following documents:

- ☒ copy of the international application as published by the International Bureau on 28 October 2004 (28.10.2004) under No. WO 2004/092213
- ☐ copy of international application as republished by the International Bureau on under No. WO
- For an explanation as to the reason for this republication of the international application, reference is made to INID codes (15), (48) or (88) (as the case may be) on the front page of the attached document.

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Philippe Becamel

Facsimile No.+41 22 740 14 35

Facsimile No.+41 22 338 71 40

AMENDED CLAIMS

JC05 Rec'd PCT/PTO 06 OCT 2005

[Received by the International Bureau on 15 November 2004 (15.11.04):
original claims 1-46 replaced by amended claims 1-46 (6 pages)]

10/552515

CLAIMS

1. An isolated polypeptide comprising:
 - (1) an amino acid sequence at least 90% homologous to SEQ ID NO: 1;
 - 5 (2) at least eight consecutive amino acids of amino acids 157-933 of SEQ ID NO: 1, wherein the isolated polypeptide is eight to ten amino acids in length and binds an MHC molecule; or
 - (3) an amino acid sequence set forth as SEQ ID NO: 1.
- 10 2. The isolated polypeptide of claim 1, comprising a polypeptide having an amino acid sequence at least 90% homologous to SEQ ID NO: 1.
3. The isolated polypeptide of claim 2, comprising an amino acid sequence at least 95% homologous to SEQ ID NO: 1.
- 15 4. The isolated polypeptide of claim 1, comprising at least eight consecutive amino acids of amino acids 157-933 of SEQ ID NO: 1, wherein the isolated polypeptide is eight to ten amino acids in length and binds an MHC molecule.
- 20 5. The isolated polypeptide of claim 1, comprising an amino acid sequence as set forth as SEQ ID NO: 1.
6. An isolated nucleic acid sequence encoding the polypeptide of claim 1.
- 25 7. The isolated nucleic acid sequence of claim 6, comprising a sequence as set forth as SEQ ID NO: 2, or a degenerate variant thereof.
8. The isolated nucleic acid sequence of claim 6, operably linked to a promoter.
- 30 9. An expression vector comprising the nucleic acid sequence of claim 6.

10. A host cell transfected with the nucleic acid sequence of claim 6.
11. The host cell of claim 10, wherein the host cell is a mammalian cell.
- 5 12. An antibody that specifically binds the polypeptide of claim 1.
13. The antibody of claim 12, wherein the antibody is a monoclonal antibody.
- 10 14. The antibody of claim 12 comprising a detectable label.
15. The antibody of claim 12, wherein the label is a fluorescent, enzymatic or radioactive label.
- 15 16. The antibody of claim 12 conjugated to a toxin.
17. A method for detecting prostate cancer in a subject, comprising
contacting a sample obtained from the subject with the antibody of claim
12 for a sufficient amount of time to form an immune complex;
20 detecting the presence the immune complex, wherein the presence of an
immune complex demonstrates the presence of prostate cancer in the subject.
18. The method of claim 17, wherein the sample is a biopsy, blood, serum, or
urine sample.
- 25 19. The method of claim 17, wherein the sample is a biopsy sample of non-
prostate origin.
20. The method of claim 17, wherein the antibody is labeled.
- 30

21. A method for detecting a prostate cancer in a subject, comprising
detecting the expression of the polypeptide of claim 1 in a sample from the
subject, wherein an increase in the expression of the polypeptide as compared to a
control indicates the presence of the prostate cancer.

5

22. The method of claim 21, wherein detecting the expression of polypeptide
comprises detecting a polypeptide having a sequence set forth as SEQ ID NO: 2 in the
sample.

10

23. The method of claim 22, wherein detecting the expression of the
polypeptide comprises
contacting the sample with an antibody that specifically binds the polypeptide
for a sufficient amount of time to form an immune complex; and
detecting the presence of the immune complex.

15

24. The method of claim 21, wherein detecting the expression of the
polypeptide comprises detecting the presence of mRNA encoding the polypeptide.

20

25. The method of claim 24, wherein detecting the presence of mRNA encoding
the polypeptide comprises a Northern Blot analysis, an RNA Dot blot, or a reverse
transcriptase polymerase chain reaction (RT-PCR) assay.

25

26. A method for producing an immune response against a cell expressing a
polypeptide of claim 1 in a subject, the method comprising
administering to the subject a therapeutically effective amount of the
polypeptide of claim 1, or a polynucleotide encoding the polypeptide, thereby
producing the immune response.

30

27. The method of claim 26, wherein the immune response is a T cell response.

28. The method of claim 26, wherein the immune response is a B cell response.

29. The method of claim 26, wherein the subject has prostate cancer.

5 30. The method of claim 29, wherein the immune response decreases the growth of the prostate cancer.

31. A method for inhibiting the growth of a malignant cell expressing the polypeptide of claim 1, the method comprising,
10 (i) culturing cytotoxic T lymphocytes (CTLs) or CTL precursor cells with the polypeptide of claim 1 to produce activated CTLs or CTL precursors that recognize an NGEP expressing cell, and
 (ii) contacting the malignant cell with the activated CTLs or CTLs matured from the CTL precursors,
15 thereby inhibiting the growth of the malignant cell.

32. A method for inhibiting the growth of a malignant cell, comprising:
 contacting the malignant cell with an effective amount of a cell-growth inhibiting molecule, wherein the cell growth inhibiting molecule comprises an antibody
20 which specifically binds a polypeptide comprising
 (1) an amino acid sequence at least 90% homologous to SEQ ID NO: 1;
 (2) at least eight consecutive amino acids of amino acids 157-933 of SEQ ID NO: 1, wherein the isolated polypeptide is eight to ten amino acids in length and binds an MHC molecule; or
25 (3) an amino acid sequence set forth as SEQ ID NO: 1;
 wherein the antibody is covalently linked to an effector molecule which inhibits the growth of cells,
 thereby inhibiting the growth of the malignant cell.

33. The method of claim 32, wherein said antibody is a monoclonal antibody.

34. The method of claim 32, wherein the effector molecule is a
chemotherapeutic agent.

5

35. The method of claim 32, wherein the effector molecule comprises a toxic
moiety.

36. The method of claim 35, wherein the toxic moiety is selected from the
group consisting of ricin A, abrin, diphtheria toxin or a subunit thereof, *Pseudomonas*
exotoxin or a portion thereof, saporin, restrictocin or gelomin.

10

37. The method of claim 35, wherein the *Pseudomonas* exotoxin is selected
from the group consisting of PE35, PE37, PE38, and PE40.

15

38. The method of claim 35, wherein the malignant cell is *in vivo*.

39. A pharmaceutical composition comprising a therapeutically effective
amount of the polypeptide of claim 1 in a pharmaceutically acceptable carrier.

20

40. A pharmaceutical composition comprising a therapeutically effective
amount of the polynucleotide of claim 6 in a pharmaceutically acceptable carrier.

41. A pharmaceutical composition comprising a therapeutically effective
amount of the antibody of claim 12 in a pharmaceutically acceptable carrier.

25

42. A method for reducing the number of prostate cancer cells in a subject,
comprising

administering to the subject a therapeutically effective amount of the polypeptide of claim 1, wherein the administration of the NGEF results in an immune response to NGEF,

thereby reducing the number of prostate cancer cells in the subject.

5

43. A method for reducing the number of prostate cancer cells in a subject, comprising

administering to the subject a therapeutically effective amount of the polynucleotide of claim 6, wherein the administration of the polynucleotide results in an immune response,

10

thereby reducing the number of prostate cancer cells in the subject.

44. A method for reducing the number of prostate cancer cells in a subject, comprising

15

administering to the subject a therapeutically effective amount of the antibody of claim 16,

thereby reducing the number of prostate cancer cells in the subject.

20

45. A kit for detecting an polynucleotide encoding NGEF in a sample, comprising

an isolated nucleic acid sequence of at least ten nucleotides in length that specifically binds to SEQ ID NO: 2 under highly stringent hybridization conditions; and instructions for the use of the isolated nucleic acid sequence.

25

46. A kit for detecting an NGEF polypeptide in a sample, comprising an monoclonal antibody that specifically binds to an antigenic epitope of SEQ ID NO: 1; and instructions for the use of the antibody.

30

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☒ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**